Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12,...

詳細記述

保存先:
書誌詳細
主要な著者: Rajkumar, S. Vincent, Hayman, Suzanne R., Lacy, Martha Q., Dispenzieri, Angela, Geyer, Susan M., Kabat, Brian, Zeldenrust, Steven R., Kumar, Shaji, Greipp, Philip R., Fonseca, Rafael, Lust, John A., Russell, Stephen J., Kyle, Robert A., Witzig, Thomas E., Gertz, Morie A.
フォーマット: Artigo
言語:Inglês
出版事項: © 2005 by The American Society of Hematology 2005
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895238/
https://ncbi.nlm.nih.gov/pubmed/16118317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-07-2817
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料